AbstractThe objective of the research was to assess risk factors for precancerous gynecological disease (PGD) in patients with breast cancer (BC) after comprehensive and combination treatment.Materials and methods. The study was based on the results of examination and treatment of 40 patients suffering from BC with PGD which developed at different times after treatment. In patients with breast cancer PGD included precancerous uterine body disease in 26 (65.0 %) patients, the precancerous ovariopathies in 9 (22.5 %) individuals and precancerous cervical disease in 5 (12.5%) cases.Results of the research. Precancerous uterine body disease occurred most often in most patients with BC after treatment. It included atypical endometrial hyperplasia in 19 (73.0%) patients and proliferating nodular leiomyoma of uterine body in 7 (27.0%) cases. Precancerous ovariopathies detected in patients with BC included allied papillary mucinous cystadenoma of ovaries in 6 (66.7%) patients and endometrioid cystadenoma in 3 (33.3%) cases. Precancerous cervical disease detected in patients with BC included severe cervical intraepithelial neoplasia (CIN III). CIN III was found in 5 (12.5%) cases. Conclusions. According to the results of the analysis and literature data, PGD occurred in patients with BC. The results indicated that hormonal factors, burdened oncology case history and results of immunohistochemical and molecular genetic diagnosis of breast tumors are important in PGD development in patients with BC.
Shchepotin IB, Fedorenko ZP. Cancer in Ukraine, 2013–2014. Morbidity, mortality, performance of oncology service. Biulleten Nats. Kantser-reiestru Ukrainy. 2014; 14: 55–56.
Smolanka II, Skliar SYu. The modern view on the problem of diagnosis and treatment of breast cancer. Zhinochyi likar. 2008; 5: 8.
Bilynskyi BT, Shparyk YaV. Problems of drug treatment of breast cancer. Posibnyk dlia likariv. 2001; 160.
Semiglazov VF, Dilman VM. The role of receptors for estrogen and progesterone in hormonal therapy appointment for patients with breast cancer in different age groups. Prakticheskaya onkologiya. 2008; 2: 26-30.
Shchepotin IB, Zotov OS, Enhel OT. Primary multiple malignant tumors of the female reproductive system. Onkologiya. 2009; 11(4): 249-253.
Miller W, Santen R. Breast cancer screening compliance among young women in a free access healthcare system. J. Surg. Oncol. 2008; 97: 20-24.
Maksimov SYa. Primary multiple tumors of the female reproductive system. Prakticheskaya onkologiya. 2009; 10(2): 117–123.
Caldarella A, Crocetti E, Taddei GL, Paci E. Coexisting endometrial and ovarian carcinomas: a retrospective clinicopathological study.. Pathol Res Pract 2008 May;204(9):643-648. Available from: https://www.nlm.nih.gov/medlineplus/ovariancancer.html PubMed PMID: 18472354. doi: 10.1016/j.prp.2008.02.001.
Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.. Dtsch Arztebl Int 2011 May;108(19):323-330. Available from: http://dx.doi.org/10.3238/arztebl.2011.0323 PubMed PMID: 21637635. doi: 10.3238/arztebl.2011.0323.
Popova TN, Selezneva TD, Barsukov VYu, Federov VYe. Peculiarities of the course and the difficulties of the diagnosis of multiple malignant neoplasms. Med. Almanakh. 2011; 2: 157–160.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.